Japan has become a victim of its own success as slowing new infections have led to a shortage of patients to enroll in trials for treatments and vaccines.
For Rocky Swift's latest contributions to The Japan Times, see below:
The Osaka-based firm got a headstart in the vaccine development by repurposing its hypertension vaccine, which had already passed various safety hurdles.
Avigan and camostat are undergoing trials as they may be effective in treating illnesses brought on by coronavirus.
To free up beds, patients requiring nonurgent surgery will likely be asked to wait, and others may be discharged earlier than usual, experts said.
Toru Itakura sipped whiskey from plastic cups as showgirls cavorted, bagpipes played and a little bit of Scotland came to Tokyo at a sampling for connoisseurs. Itakura, a bar owner in Yokohama, finally chose a Scotch, as well as Ichiro's Malt, a little-known Japanese brand. "The ...